ReviewCNS drugs2015
Antiepileptic Drug Treatment in Children with Epilepsy.
Review in CNS drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 6 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- Efficacy and safety of Brivaracetam as adjunctive therapy in pediatric epilepsy: A systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Pooled it
- EANM practice guidelines for an appropriate use of PET and SPECT for patients with epilepsy.European journal of nuclear medicine and molecular imaging · 2024Guideline
- The reference range of lamotrigine in the treatment of epilepsy in children: a systematic review.European journal of clinical pharmacology · 2024Pooled it
- Parent perceptions and decision making about treatments for epilepsy: a qualitative evidence synthesis.BMJ open · 2023Pooled it
- Association between SCN1A polymorphism rs3812718 and valproic acid resistance in epilepsy children: a case-control study and meta-analysis.Bioscience reports · 2018Pooled it
- Adjunctive Eslicarbazepine Acetate in Pediatric Patients with Focal Epilepsy: A Systematic Review and Meta-Analysis.CNS drugs · 2018Pooled it
- Trial
- Pediatric occipital lobe epilepsy: A modern review of etiological classification, management, and outcomes.World journal of clinical pediatrics · 2026Review
- Parental miscarried helping, self-efficacy, and treatment adherence among adolescents and young adults with epilepsy: A mediation model.Epilepsy research · 2026Article
- Article
- Optimization of individualized therapy with oral valproic acid in pediatric patients with epilepsy based on factors influencing blood concentrations.Frontiers in pharmacology · 2026Article
- Global, regional and national burden of epilepsy in children and adolescents, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021.European journal of clinical investigation · 2026Article
- The potential of laminar functional MRI in refining the understanding of epilepsy in humans.Brain : a journal of neurology · 2025Review
- Article
- Evaluating the serum levels of zinc, copper, magnesium, and 25-hydroxy vitamin D in children with idiopathic drug-resistant epilepsy; a cross-sectional study.BMC pediatrics · 2024Article
- KCNT1 Channel Blockers: A Medicinal Chemistry Perspective.Molecules (Basel, Switzerland) · 2024Review
- Efficacy and safety of a smartphone application-based treatment of ketogenic diet in pediatric refractory epilepsy.Epilepsia open · 2024Article
- Slipped capital femoral epiphysis in a 5-year-old boy with cerebral palsy on valproic acid and levetiracetam for epilepsy: a case report.Journal of surgical case reports · 2024Article
- Longitudinal exposure to antiseizure medications shape gut-derived microbiome, resistome, and metabolome landscape.ISME communications · 2024Article
- Anti-seizure Medications: Challenges and Opportunities.CNS & neurological disorders drug targets · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most children with new-onset epilepsy achieve seizure freedom with appropriate antiepileptic drugs (AEDs). However, nearly 20 % will continue to have seizures despite AEDs, as either monotherapy or in combination. Despite the growing market of new molecules over the last 20 years, the proportion of drug-resistant epilepsies has not changed. In this review, we report the evidence of efficacy and safety based on phase III randomized controlled clinical trials (RCTs) of AEDs currently used in the paediatric population. We conducted a literature search using the PubMed database and the Cochrane Database of Systematic Reviews. We also analysed the RCTs of newer AEDs whose efficacy in adolescents and adults might suggest possible use in children. Most of the phase III trials on AEDs in children have major methodological limitations that considerably limit meaningful conclusions about comparative efficacy between old and new molecules. Since the efficacy of new drugs has only been reported versus placebo, the commonly held opinion that new and newer AEDs have a better safety profile than old ones does not appear to be supported by evidence. Despite limited solid evidence, pharmacological management has improved over the years as a consequence of increased awareness of some degree of specificity of treatment in relation to different epilepsy syndromes and attention to adverse events. Future research should be directed taking these factors, as well as the diversity of epilepsy, into consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.